Forecasting Stories

ADI
  over three months ago at Macroaxis 
By Ellen Johnson
Analog Devices Working Capital is most likely to decrease significantly in the upcoming years. The last year's value of Working Capital was reported at 1.04 Billion. The current Interest Coverage is estimated to increase to 9.36, while Revenue Per Employee is projected to decrease to roughly 307.8 K. Today's short post will concentrate on Analog Devices as your potential position. We will examine the question of why stockholders should continue to be confident in Analog Devices outlook.
JKHY
  over three months ago at Macroaxis 
By Rifka Kats
Jack Henry Net Current Assets as percentage of Total Assets are fairly stable at the moment as compared to the past year. Jack Henry reported Net Current Assets as percentage of Total Assets of 6.46 in 2020. Asset Turnover is likely to rise to 0.88 in 2021, whereas Net Income Per Employee is likely to drop slightly above 37.1 K in 2021. This short post will break down Jack Henry as a possible investment alternative for your portfolios. We will provide a perspective on Jack Henry future direction.
FN
  over three months ago at Macroaxis 
By Vlad Skutelnik
Fabrinet EBITDA Margin is quite stable at the moment as compared to the past year. The company's current value of EBITDA Margin is estimated at 0.1. Free Cash Flow per Share is expected to rise to 0.08 this year, although the value of Average Assets will most likely fall to about 963.4 M. Today's short post will outline Fabrinet as your potential position. We will inspect the question of why institutional investors should continue to be confident in Fabrinet outlook.
REPH
  over three months ago at Macroaxis 
By Rifka Kats
Recro Pharma Tangible Asset Value is most likely to increase significantly in the upcoming years. The preceding year's Tangible Asset Value was reported at 83.01 Million. The current Working Capital is estimated to increase to about 28.3 M, while Net Income Per Employee is projected to decrease to (160 K). The intention for this outlook is to give stockholders our take on Recro future value. We will examine the reasons why it could be a game-changer for Recro Pharma stockholders.
APYX
  over three months ago at Macroaxis 
By Ellen Johnson
Apyx Medical Debt Non Current is fairly stable at the moment as compared to the past year. Apyx Medical reported Debt Non Current of 312,000 in 2020. Goodwill and Intangible Assets is likely to rise to about 176.4 K in 2021, whereas Average Assets are likely to drop slightly above 65.6 M in 2021. In this article, we will break down Apyx Medical as a potential position in addition to your existing holdings. We will inspect why it could be a game-changer for Apyx Medical investors.
SPPI
  over three months ago at Macroaxis 
By Raphi Shpitalnik
Spectrum Pharma Average Equity is most likely to increase significantly in the upcoming years. The last year's value of Average Equity was reported at 200.72 Million. The current Free Cash Flow is estimated to increase to about 6.3 M, while Net Income Per Employee is projected to decrease to (935.5 K). This short post will concentrate on Spectrum Pharma as a possible investment alternative for your portfolios. We will provide a perspective on Spectrum Pharma future direction.
ING
  over three months ago at Macroaxis 
By Raphi Shpitalnik
Ingles Markets Net Income Per Employee is projected to increase significantly based on the last few years of reporting. The past year's Net Income Per Employee was at 2,114. The current year Revenue Per Employee is expected to grow to about 177.7 K, whereas Interest Coverage is forecasted to decline to 2.60. This short post will go over Ingles Markets as a possible investment alternative for your portfolios. We will provide a perspective on Ingles Markets future direction.
ING
  over three months ago at Macroaxis 
By Ellen Johnson
Ingles Markets Net Income Per Employee is projected to increase significantly based on the last few years of reporting. The past year's Net Income Per Employee was at 2,114. The current year Revenue Per Employee is expected to grow to about 177.7 K, whereas Interest Coverage is forecasted to decline to 2.60. The basic aim of this article is to give investors our perspective on Ingles for September. We will forecast Ingles Markets value for investors.
COHR
  over three months ago at Macroaxis 
By Vlad Skutelnik
Coherent Interest Coverage is relatively stable at the moment as compared to the past year. Coherent reported last year Interest Coverage of 11.06. As of 08/11/2021, Long Term Debt to Equity is likely to grow to 0.55, while Average Assets are likely to drop slightly above 2 B. Today's short post will sum up Coherent as your potential position. We will discuss the question of why retail investors should continue to be confident in Coherent outlook.
CBAY
  over three months ago at Macroaxis 
By Raphi Shpitalnik
Cymabay Therapeutics Net Cash Flow from Investing is fairly stable at the moment as compared to the past year. Cymabay Therapeutics reported Net Cash Flow from Investing of 47.96 Million in 2020. Net Cash Flow Investment Acquisitions and Disposals is likely to rise to about 51.8 M in 2021, whereas Average Assets are likely to drop slightly above 143.2 M in 2021. Today's short post will break down Cymabay Therapeutics as your potential position. We will inspect the question of why investors should continue to be confident in Cymabay Therapeutics outlook.